Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1995 Jul;96(1):38–41. doi: 10.1172/JCI118045

The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor.

D Burger 1, R Chicheportiche 1, J G Giri 1, J M Dayer 1
PMCID: PMC185170  PMID: 7615809

Abstract

Interleukin-1 (IL-1) is a major proinflammatory cytokine produced by monocytes/macrophages. At the inflammatory site, IL-1 is a potent inducer of the production of prostaglandin E2 (PGE2) and metalloproteinases on fibroblast-like cells, thus triggering tissue damage. The biological activity of IL-1 is counterbalanced by two types of inhibitors: the IL-1 receptor antagonist (IL-1Ra) which competitively binds IL-1 receptor without inducing signal transduction; and IL-1 soluble receptors (IL-1sR) which bind IL-1 and diminish the free concentration of soluble cytokine, thus hampering its binding to the cell surface receptor. Since IL-1sR can also bind IL-1Ra, we studied the simultaneous effects of both inhibitors on the production of interstitial collagenase (C'ase) and PGE2 by human dermal fibroblasts and synovial cells stimulated by either IL-1 alpha or IL-1 beta. IL-1Ra inhibited fibroblast and synovial cell stimulation by approximately 90%, with the exception of C'ase production by synovial cells which was inhibited by approximately 55%. Type I IL-1sR (IL-1sRI) preferentially inhibited IL-1 alpha, whereas type II IL-1sR (IL-1sRII) mainly inhibited IL-1 beta. When IL-1Ra was used simultaneously with IL-1sRI, the final inhibition was lower than that of either of the inhibitors. The simultaneous presence of IL-1Ra and IL-1sRII abolished the IL-1-induced production of PGE2 and C'ase on both dermal fibroblasts and synovial cells, demonstrating that concurrently these two inhibitors are able to abolish most of the inflammatory response. To our knowledge, this is the first example of two types of inhibitors that abolish each other's effects, one of which acts at the receptor level and the other at the ligand level, thus leaving ligand activity unimpaired.

Full text

PDF
41

Images in this article

39Image
on p.39
40Image
on p.40

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arend W. P., Dayer J. M. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum. 1990 Mar;33(3):305–315. doi: 10.1002/art.1780330302. [DOI] [PubMed] [Google Scholar]
  2. Arend W. P. Interleukin-1 receptor antagonist. Adv Immunol. 1993;54:167–227. doi: 10.1016/s0065-2776(08)60535-0. [DOI] [PubMed] [Google Scholar]
  3. Burke F., Naylor M. S., Davies B., Balkwill F. The cytokine wall chart. Immunol Today. 1993 Apr;14(4):165–170. doi: 10.1016/0167-5699(93)90280-x. [DOI] [PubMed] [Google Scholar]
  4. Chensue S. W., Bienkowski M., Eessalu T. E., Warmington K. S., Hershey S. D., Lukacs N. W., Kunkel S. L. Endogenous IL-1 receptor antagonist protein (IRAP) regulates schistosome egg granuloma formation and the regional lymphoid response. J Immunol. 1993 Oct 1;151(7):3654–3662. [PubMed] [Google Scholar]
  5. Dayer J. M., Bréard J., Chess L., Krane S. M. Participation of monocyte-macrophages and lymphocytes in the production of a factor that stimulates collagenase and prostaglandin release by rheumatoid synovial cells. J Clin Invest. 1979 Nov;64(5):1386–1392. doi: 10.1172/JCI109596. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Eastgate J. A., Symons J. A., Duff G. W. Identification of an interleukin-1 beta binding protein in human plasma. FEBS Lett. 1990 Jan 29;260(2):213–216. doi: 10.1016/0014-5793(90)80106-s. [DOI] [PubMed] [Google Scholar]
  7. Ferretti M., Casini-Raggi V., Pizarro T. T., Eisenberg S. P., Nast C. C., Cominelli F. Neutralization of endogenous IL-1 receptor antagonist exacerbates and prolongs inflammation in rabbit immune colitis. J Clin Invest. 1994 Jul;94(1):449–453. doi: 10.1172/JCI117345. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Giri J. G., Newton R. C., Horuk R. Identification of soluble interleukin-1 binding protein in cell-free supernatants. Evidence for soluble interleukin-1 receptor. J Biol Chem. 1990 Oct 15;265(29):17416–17419. [PubMed] [Google Scholar]
  9. Lacraz S., Nicod L., Galve-de Rochemonteix B., Baumberger C., Dayer J. M., Welgus H. G. Suppression of metalloproteinase biosynthesis in human alveolar macrophages by interleukin-4. J Clin Invest. 1992 Aug;90(2):382–388. doi: 10.1172/JCI115872. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Martel-Pelletier J., McCollum R., DiBattista J., Faure M. P., Chin J. A., Fournier S., Sarfati M., Pelletier J. P. The interleukin-1 receptor in normal and osteoarthritic human articular chondrocytes. Identification as the type I receptor and analysis of binding kinetics and biologic function. Arthritis Rheum. 1992 May;35(5):530–540. doi: 10.1002/art.1780350507. [DOI] [PubMed] [Google Scholar]
  11. McMahan C. J., Slack J. L., Mosley B., Cosman D., Lupton S. D., Brunton L. L., Grubin C. E., Wignall J. M., Jenkins N. A., Brannan C. I. A novel IL-1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types. EMBO J. 1991 Oct;10(10):2821–2832. doi: 10.1002/j.1460-2075.1991.tb07831.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Opdenakker G., Van Damme J. Cytokines and proteases in invasive processes: molecular similarities between inflammation and cancer. Cytokine. 1992 Jul;4(4):251–258. doi: 10.1016/1043-4666(92)90064-x. [DOI] [PubMed] [Google Scholar]
  13. Rothe J., Gehr G., Loetscher H., Lesslauer W. Tumor necrosis factor receptors--structure and function. Immunol Res. 1992;11(2):81–90. doi: 10.1007/BF02918612. [DOI] [PubMed] [Google Scholar]
  14. Seckinger P., Kaufmann M. T., Dayer J. M. An interleukin 1 inhibitor affects both cell-associated interleukin 1-induced T cell proliferation and PGE2/collagenase production by human dermal fibroblasts and synovial cells. Immunobiology. 1990 Jun;180(4-5):316–327. doi: 10.1016/S0171-2985(11)80295-0. [DOI] [PubMed] [Google Scholar]
  15. Sims J. E., Acres R. B., Grubin C. E., McMahan C. J., Wignall J. M., March C. J., Dower S. K. Cloning the interleukin 1 receptor from human T cells. Proc Natl Acad Sci U S A. 1989 Nov;86(22):8946–8950. doi: 10.1073/pnas.86.22.8946. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Slack J., McMahan C. J., Waugh S., Schooley K., Spriggs M. K., Sims J. E., Dower S. K. Independent binding of interleukin-1 alpha and interleukin-1 beta to type I and type II interleukin-1 receptors. J Biol Chem. 1993 Feb 5;268(4):2513–2524. [PubMed] [Google Scholar]
  17. Svenson M., Hansen M. B., Heegaard P., Abell K., Bendtzen K. Specific binding of interleukin 1 (IL-1) beta and IL-1 receptor antagonist (IL-1ra) to human serum. High-affinity binding of IL-1ra to soluble IL-1 receptor type I. Cytokine. 1993 Sep;5(5):427–435. doi: 10.1016/1043-4666(93)90032-z. [DOI] [PubMed] [Google Scholar]
  18. Symons J. A., Duff G. W. A soluble form of the interleukin-1 receptor produced by a human B cell line. FEBS Lett. 1990 Oct 15;272(1-2):133–136. doi: 10.1016/0014-5793(90)80466-v. [DOI] [PubMed] [Google Scholar]
  19. Symons J. A., Eastgate J. A., Duff G. W. A soluble binding protein specific for interleukin 1 beta is produced by activated mononuclear cells. Cytokine. 1990 May;2(3):190–198. doi: 10.1016/1043-4666(90)90015-l. [DOI] [PubMed] [Google Scholar]
  20. Symons J. A., Eastgate J. A., Duff G. W. Purification and characterization of a novel soluble receptor for interleukin 1. J Exp Med. 1991 Nov 1;174(5):1251–1254. doi: 10.1084/jem.174.5.1251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Tiesman J., Hart C. E. Identification of a soluble receptor for platelet-derived growth factor in cell-conditioned medium and human plasma. J Biol Chem. 1993 May 5;268(13):9621–9628. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES